“An experimental compound called PA-915, a PAC1 receptor antagonist, has been developed as 'the world's first anti-anxiety vaccine' and in animal studies a single dose significantly reduced anxiety and depression symptoms for weeks." Related in-post claims: "effects similar to an anti-anxiety vaccine"; "a result not seen with existing…”

The underlying study is real, peer-reviewed, and published in a high-impact journal. The researchers describe PA-915 as a small-molecule, non-peptide, high-affinity PAC1 antagonist, and had previously demonstrated that it suppresses anxiety-like behavior in acute stress-induced mice. The study investigated PA-915 in chronic stress-induced mouse models of depression, including repeated social defeat stress, repeated corticosterone administration, and social isolation rearing, and found PA-915 reduced increased immobility time in the forced swim test in these mice. In repeated social defeat stress mice, PA-915 improved anxiety-like and depression-like behaviors and cognitive dysfunction across the light-dark, open field, elevated plus maze, sucrose preference, forced swim, Y-maze, and novel object recognition tests, and the compound was compared with ketamine and fluoxetine. The key duration finding: in the sucrose preference test, an antidepressant-like effect was observed for 8 weeks in mice that received a single dose of PA-915, an effect similar to that observed with ketamine, while in non-stressed control mice PA-915 did not induce behavioral abnormalities such as hyperlocomotion, cognitive dysfunction, or dependency. The authors state that a single PA-915 administration attenuated anxiety- and depression-like behaviors and cognitive dysfunction, with antidepressant-like effects lasting at least 8 weeks. The institutional press release confirms the scope: researchers from the University of Osaka, University of Toyama, Hiroshima University and Kagoshima University demonstrated that the PAC1 antagonist exhibits rapid and long-lasting antidepressant effects in animal models of depression after a single administration. Critically, no source describes PA-915 as a vaccine. Journalism examining the viral framing states plainly: vaccines work through the immune system, whereas PA-915 works on the brain's stress-response system; it is a drug, a specially designed molecule developed by researchers in Japan that has so far only been tested in mice. Social media has been flooded with headlines about the world's first "anti-anxiety vaccine," but there is an important asterisk: it is not actually a vaccine, it is a molecule. Even outlets amplifying the story concede the point: researchers are being described as calling it an "anti-anxiety vaccine," though that description requires clarification. **METHODOLOGY AND CONTEXT** - **Design**: Preclinical animal study. Male C57BL/6N mice. Three chronic stress models (repeated social defeat stress, repeated corticosterone, social isolation rearing). - **Route and dose**: Per the patent filing, chronic social defeat stress was applied for 10 days to male mice, susceptible animals were selected via a social preference or avoidance test, and on the following day vehicle or PA-915 at 30 mg/kg was administered intraperitoneally. This is injection into the abdominal cavity, not an oral or subcutaneous "shot" in the vaccine sense. Separately, a supplier datasheet describes PA-915 as orally active in other contexts. - **Comparators**: Ketamine and fluoxetine. - **Primary behavioral endpoints**: Sucrose preference (anhedonia proxy), forced swim immobility, light-dark and elevated plus maze (anxiety proxies), Y-maze and novel object recognition (cognition proxies). - **Duration finding**: At least 8 weeks, established specifically in the sucrose preference test, a depression-like endpoint. - **Human data**: None found. No registered clinical trial identified in searching. - **Effect sizes and confidence intervals**: Not retrieved in the abstract-level material available here.